CVM

#4465
Cel-Sci Corporation
4.3300 USD
+7.96%
부문: 헬스케어
베이스: USD
수익 통화: USD
일일 변동 비율
4.1800
4.3300
년간 변동
3.0164
5.1500
일일 변동
+7.96%
월간 변동
+20.28%
6달 변화
-15.92%
년간 변동율
-15.92%
이전 종가
4.0106
Open
4.1800
Bid
Ask
Low
4.1800
High
4.3300
양
5
Open full chart

Financials

Overview 성명 Statistics
Quarterly Annual
  • Market Capitalization 36.623 M
  • Employee 44
  • Founded N/A
  • CEO N/A
  • Website www.cel-sci.com
  • Headquarter Colorado, United States
  • FIGI BBG000H5G6L5
  • Industry Technology
총매출
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
-1.47
Price to sales ratio
-57.5

Cel-Sci Corporation

Cel-Sci Corporation, is a biotechnology company that tests drugs for the treatment of cancer, autoimmune and infectious diseases through the research and development of immunotherapy products. Cel-Sci's main product is the drug Multikine, an immunotherapeutic agent designed to fight cancer by stimulating the body's immune system. Multikine is currently in Phase III of Clinical Trials with the Food and Drug Administration. Multikine has also been referred to as Leukocyte Interleukin Injection. Multikine was in Phase II testing of patients with head and neck cancer in the early 2000s, in which it demonstrated tumor-reducing ability. In January 2007, the US cleared the Phase 3 trial and Multikine was designated as an orphan drug by the FDA for neoadjuvant therapy of patients with squamous cell carcinoma of the head and neck. A total of 928 patients were enrolled in the head and neck cancer drug trial at that time. Subsequently, in June 2021, the company announced that the study missed its primary endpoint.

뉴스